INTRODUCTION
============

Carpal tunnel syndrome (CTS) is a chronic compressive neuropathy that is caused by median nerve entrapment in the carpal tunnel and is the most common entrapment neuropathy ([@b1-jer-14-6-1067]; [@b18-jer-14-6-1067]). This syndrome is the most expensive upper extremities musculoskeletal problem. In the United States, it costs about \$10 billion annually (due to the need for surgery) ([@b27-jer-14-6-1067]).

Carpal tunnel is an osteofibrous canal that contains nine flexor tendons (flexor pollicis longus, four flexor digitorum superficialis, four flexor digitorum profundus) and median nerve ([@b22-jer-14-6-1067]). CTS is manifested by paresthesia (exacerbating at night), numbness, tingling, and pain in the median nerve area ([@b6-jer-14-6-1067]; [@b9-jer-14-6-1067]).The prevalence of the disease is 5.3% in women and 2.1% in men ([@b25-jer-14-6-1067]) and CTS has a prevalence rate of 7.8% and annual incidence rate of 5.7% in the working population ([@b8-jer-14-6-1067]).

Risk factors reported for CTS include diabetes ([@b20-jer-14-6-1067]), hypothyroidism ([@b13-jer-14-6-1067]), rheumatologic diseases and occupational factors ([@b19-jer-14-6-1067]). In addition to the cost of surgical treatment, there are various reasons for the choice of nonsurgical and preservative treatment, including postoperative complications such as infection, nerve damage, tendon injury, and reflex sympathetic dystrophy syndrome ([@b17-jer-14-6-1067]). Therefore, the selection of appropriate nonsurgical treatment is very important when facing this common and costly disease.

Gabapentin is one of the medications used in neuropathic pain which is effective in reducing neuropathic pain in trigeminal neuralgia, diabetic neuropathy, post herpetic neuralgia, and reflex sympathetic dystrophy syndrome ([@b2-jer-14-6-1067]; [@b23-jer-14-6-1067]; [@b24-jer-14-6-1067]). There are some discrepancies in literature about the degrees of effectiveness of gabapentin ([@b9-jer-14-6-1067]; [@b11-jer-14-6-1067]) and exercises in treatment of CTS ([@b5-jer-14-6-1067]; [@b28-jer-14-6-1067]).

In the severe type and advanced stages of the CTS, the median nerve gets an hour-glass deformity due to narrowing under the thickened flexor retinaculum with swelling over the distal and proximal region, and the nerve injury is irreversible ([@b16-jer-14-6-1067]). Therefore, the study of noninvasive treatments in early stages of the disease is necessary in order to prevent the progression of the disease, waste of time, cost; and to obtain the most comprehensive treatment. The aim of this study was to evaluate the effectiveness of splinting, gabapentin, exercises and combinations of these conservative therapies in treatment of mild to moderate CTS.

MATERIALS AND METHODS
=====================

Trial design
------------

This study was approved by the Ethics Committee of the Shahid Beheshti University of Medical Sciences in Iran (IR.SBMU.MSP.REC.A396.59). The study was a single-blind clinical controlled trial that was conducted in patients referred to the electrodiagnostic (EDX) unit of Imam Hossein hospital.

Inclusion criteria
------------------

The inclusion criteria of this study were: (a) presence of sensory symptoms in median nerve area for more than 3 months, and (b) EDX evidence of entrapment of median nerve due to CTS. People who met one of the following criteria were excluded from the study: evidence of severe entrapment including atrophy of the thenar muscles and EDX studies indicating severe nerve entrapment (due to the need for referral for surgery); EDX and clinical examination evidence of conditions that mimic the CTS such as cervical radiculopathy, polyneuropathy, and proximal median neuropathies; taking antiepileptic and tricyclic antidepressant for other reasons; taking oral and injectable corticosteroids in the last three months; diabetes mellitus; hypothyroidism; pregnancy; rheumatologic diseases; trauma; doing similar exercises during last month; history of suicidal ideation or suicidal attempts; and a creatinine clearance level less than 30. People who were sensitive to side effects of gabapentin or those who were not able to continue their participation in the study were excluded and replaced.

Intervention
------------

Patients with mild to moderate CTS were randomly assigned to one of the four intervention groups:

a.  Using nocturnal cock-up splint as an approved treatment in the control group.

b.  Taking 300-mg gabapentin per night and using nocturnal splint.

c.  Using nocturnal splint and performing daily exercises that each type of exercise should be done 10 times per day. The exercises include nerve gliding exercise, tendon gliding exercise, stretching, and griping.

d.  Taking 300-mg gabapentin per night, performing same exercise as group 3 and using nocturnal splint.

The diagnosis of CTS was based on the presence of paresthesia and pain with the same characteristics of CTS' symptoms. The diagnosis was confirmed and severity of CTS was determined using electromyography (EMG). The following definition for severity of CTS (mild, moderate, and severe) based on EMG evidences was used in this study:

1.  Mild: median distal sensory peak latency prolongation, either absolute or relative (using sensitive comparative methods) and no evidence of axon loss.

2.  Moderate: abnormal median sensory latency, as noted in the mild type, and absolute or relative prolongation of median motor distal latency (using sensitive comparative methods), and lack of evidence of axon loss.

3.  Severe: any disturbances in nerve conduction studies mentioned above, along with evidence of axon loss, defined as: (a) lack or decreased amplitude of sensory nerve action potential or mixed nerve action potential of median nerve (b) lack of or decreased amplitude of thenar compound muscle action potential; or (c) the presence of fibrillation potentials or changes in motor unit potentials such as increasing amplitude, duration or phases in needle EMG ([@b29-jer-14-6-1067]).

Randomization
-------------

All patients gave informed consent before being entered into the study. Side effects of the medication were explained to patients. Participants were advised to stop taking the medication if they have side effects. Recruitment to the trial was done using convenience sampling. The randomization of patients for assigning to intervention groups was done through stratified permutation blocks method, where the severity of the disease was taken into account as a block.

Measurement
-----------

The following measures were used to assess patients before and 1 month after treatment: (a) Visual analogue scale (VAS) for assessment of pain and paresthesia; (b) Boston carpal tunnel questionnaire (BCTQ) including symptom severity scale (SSS) and functional status scale (FSS) for evaluating the treatment effectiveness; (c) Grip strength was measured by SAEHAN hydraulic handgrip dynamometer (Model SH5001; SAEHAN Corp., Seoul, Korea); (d) Pinch strength was measured by SAEHAN hydraulic pinch dynamometer (Model SH5005).

Self-report questionnaire
-------------------------

Severity of symptoms and functional status were assessed using the BCTQ that is a self-administered and self-report questionnaire ([@b14-jer-14-6-1067]). The BCTQ consists of two parts: SSS and FSS. The SSS evaluates symptoms such as pain, numbness, weakness, and paresthesia using 11 questions. FSS evaluates problems in everyday activities such as writing, dressing, keeping a book while reading, and etc. using eight questions. The SSS items' score can range from 1 (no symptoms) to 5 (severe). The FSS items' score can range from 1 (no dysfunction) to 5 (disability due to symptoms).

Pain and paresthesia were measured using VAS. The severity of pain was categorized between 0 and 10, in which 0 means no pain and 10 means the worst possible pain. Patients were asked to match their pain according to VAS scale ([@b9-jer-14-6-1067]).

Performance-based outcome measures
----------------------------------

To measure grip strength, a dynamometer was used which was a sensitive and repeatable tool. First, the participants were taught how to use the device. Then, patients were asked to do the test once to familiarize with the device. After giving rest to their wrist, the actual test was performed. Participants were given three chances to apply their maximum force, and the average was calculated.

A pinch meter was used to measure pinch strength and maximum force in palmar pinch was measured.

Tendon gliding exercises
------------------------

All patients were trained by a sports medicine specialist on tendon and nerve gliding exercises that patients should do at home. In these exercises, fingers are located in five different positions including straight, hook, fist, tabletop, and straight fist.

Nerve gliding exercise
----------------------

In order to enable the mobilization of the median nerve, patients need to perform the exercise in a way that the hand and wrist would be in six different positions:

a.  The wrist is in neutral position, the fingers and thumb are in flexion.

b.  The wrist is in neutral position, the fingers and thumb are in extension.

c.  The wrist and fingers are in extension, the thumb is in neutral position.

d.  The wrist, fingers, and thumb are in extension.

e.  As position 4, but forearm is in supination.

f.  As position 5, but gently stretching the thumb with the other hand ([@b15-jer-14-6-1067]).

Two hundred thirty patients were referred to the sports medicine clinic of Imam Hossein hospital after their diagnosis was confirmed by EDX studies. Preintervention assessments were done by a neurologist and provided to the sports medicine specialist. The sports medicine specialist identified four treatment groups based on the permutation blocks randomization method (was done by statistician), while the neurologist did not know about the type of treatment group. The sample size was calculated considering the attrition rate. Therapeutic exercises were taught to the patients in groups 3 and 4 by a sports medicine specialist, and a sheet with of photos of each step was provided to these groups. After 1 month, patients were reassessed by the neurologist using BCTQ, VAS, pinch and grip strength with a dynamometer, while the neurologist was not aware of the patient's treatment group. The data were entered in the table by the sports medicine specialist.

Analysis
--------

Distribution of underlying variables such as gender, body mass index (BMI), disease state, and age in intervention groups, was analyzed using one-way analysis of variance (ANOVA), chi-square and Fisher exact test, depending on the type of variables. Finally, one-way ANOVA was used to evaluate the effect of intervention groups on the difference between postintervention scores and baseline scores. *P*-value less than 0.05 was considered meaningful. All analyzes were performed using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). Tukey *post hoc* test was used to compare each group with other groups. Dunnett *post hoc* test was used to compare each group with the control group. Analysis of covariance was used to compare postintervention response values among the intervention groups. In this method, the dependent variable at baseline, along with other underlying variables as covariates, was entered into the model, so that its effect, if available, can be considered on the response.

RESULTS
=======

A total of 82 out of 230 patients (eligible) were entered in the study and completed the 1-month follow-up ([Fig. 1](#f1-jer-14-6-1067){ref-type="fig"}). In this study, 88% of participants were female. Most of the patients were overweight or obese. BMI of about 88% of patients was greater than normal. Majority of participants (67.1%) has mild CTS.

As presented in [Table 1](#t1-jer-14-6-1067){ref-type="table"}, distribution of BMI and gender are not the same among groups, while the severity of the disease is roughly distributed the same among groups. There was a statistically significant difference between the groups in terms of mean age of the patients ([Table 1](#t1-jer-14-6-1067){ref-type="table"}). The youngest patient was 24 years old and the oldest patient was 74 years old. Half of all patients were over 46 years of age.

As shown in [Table 2](#t2-jer-14-6-1067){ref-type="table"}, in patients with mild CTS, there was no statistically significant difference between groups in postintervention mean of Boston.SSS, Boston.FSS, pinch strength, and VAS, indicating no difference between intervention groups and control group. However, grip strength was not significantly higher in group 4 (gabapentin+exercise) compared to control group (*P*= 0.048).

In patients with moderate CTS, there was no significant difference in BCTQ indices after treatment comparing with control group; but in pinch, grip, and VAS, there was a significant difference in mean after treatment. This difference was observed in those who received gabapentin and did exercises.

DISCUSSION
==========

CTS treatments are based on the removal of pressure from median nerve and according to literature, using splint is an appropriate treatment for mild and moderate CTS ([@b4-jer-14-6-1067]; [@b21-jer-14-6-1067]). Nocturnal splints usually are prescribed for patient in order to prevent interference with daily activities. Another method of reducing the pressure of the carpal tunnel is to stop the inflammation using anti-inflammatory agents ([@b10-jer-14-6-1067]). A recent systematic review study reported that according to experimental evidence, oral steroids, and corticosteroid injections help patients with CTS in the short term, however, they are not effective in long term ([@b12-jer-14-6-1067]). Given systemic complications of oral steroids and potential side effects of diuretics on cardiovascular system, some studies reported using other drug combinations for treatment of CTS ([@b10-jer-14-6-1067]). Because gabapentin is used in treatment of neuropathic pain, in some studies it has been used to treat CTS, including a double-blind clinical trial conducted in 2010 in which 140 patients recently diagnosed with CTS were assigned to two groups receiving either placebo or 900-mg gabapentin daily for at least 3 months. The global symptom score (GSS) was used at baseline, 2 and 8 weeks. GSS score is based on how patients rate their symptoms of pain, numbness, tingling, weakness and clumsiness, and nightly awakening. According to the results, there was no statistically significant difference between the group receiving gabapentin and the group that received placebo ([@b11-jer-14-6-1067]).

In contrast to the above mentioned study, in another study, patients with mild to moderate CTS (diagnosed based on clinical signs and EDX evidence) were assigned into three treatment groups: (a) control group, (b) 100-mg gabapentin daily, and (c) 300-mg gabapentin daily. All three groups received splint. Patients were assessed at baseline and after 2 months in terms of five indicators including pinch and grip strength, VAS, BCTQ, and NCS. The two treatment groups got better scores comparing to control group for all measures except for NCS. The participants who received 300-mg gabapentin had significantly better scores in SSS and pinch strength compared with those who received 100-mg gabapentin ([@b9-jer-14-6-1067]).

According to our study, there was no significant difference between patients who received gabapentin and used splint and control group in patient with mild and moderate CTS. However, there was a significant difference between group 4 (gabapentin+splint+ exercise) and control group, especially in the moderate CTS.

In another study conducted in 2018, 41 patients assigned to two groups, one received splints and the other one received splint, tendon/nerve gliding exercise and ultrasound for treatment of CTS. They were evaluated pre and postintervention using BCTQ and no significant difference between the two groups was reported. In this study, drug combinations such as gabapentin have not been used and therapeutic outcomes have been reported in one general group with patients with different severities, and have not been studied in the mild to moderate severity group ([@b26-jer-14-6-1067]).

In another study, manipulative method that included griping and stretching movements was compared with the control group (without treatment). Participants were assessed using daily VAS, the functional table completed by participants and range of motion test. Patients in manipulative method group showed significant improvement compared to control group. In this study, the severity of CTS was not determined and it was only stated that more patients in control group were in need of surgery compared to intervention group ([@b28-jer-14-6-1067]).

To compare the effect of neutral wrist and metacarpophalangeal (MCP) splint with a wrist cock-up splint with and without exercise, 61 patients with mild to moderate CTS were assigned to four groups; of those, 51 patients completed the treatment. Participants were assessed using the Boston SSS and FSS at baseline, 4 weeks and 8 weeks. The results showed that participants who used neural wrist and MCP splint had better outcomes compared to those who used a cock-up splint. Exercise was not significantly effective in comparison to the splint group ([@b7-jer-14-6-1067]).

In a systematic review study that focused on the therapeutic role of nerve gliding exercises in treating patients with CTS, it has been reported that a few studies have found nerve gliding exercises an effective method in treatment of patients with CTS. Authors of this study emphasized on the need for more studies to find out the effectiveness of available treatments for CTS ([@b3-jer-14-6-1067]).

This study showed that using nocturnal splint along with exercise and taking gabapentin improved VAS, pinch and grip strength compared to control group that only used the nocturnal splint, especially in moderate CTS.
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![Flow chart of trial and number of patients. From 230 patients of eligibility, 98 patients were randomized and 82 patients completed the course of intervention.](jer-14-6-1067f1){#f1-jer-14-6-1067}

###### 

Demographic data and preintervention status of patients in different groups

  Characteristic                                      Exercise      Gabapentin   Exercise+ gabapentin   Control      *P*-value
  --------------------------------------------------- ------------- ------------ ---------------------- ------------ -----------
  Age (yr)                                            54.17±9.99    41.04±8.46   47.13±9.14             48.30±9.96   \<0.001
                                                                                                                     
  Gender                                                                                                             0.006
   Male                                               6 (26.1)      0 (0)        0 (0)                  4 (20)       
   Female                                             17 (73.9)     23 (100)     16 (100)               16 (80)      
                                                                                                                     
  BMI[a)](#tfn3-jer-14-6-1067){ref-type="table-fn"}                                                                  0.04
   Normal                                             2 (8.7)       0 (0)        5 (31.3)               3 (15)       
   Overweight                                         9 (39.1)      12 (52.2)    9 (56.3)               9 (45)       
   Obesity grade I                                    7 (30.4)      10 (43.5)    2 (12.5)               7 (35)       
   Obesity grade II                                   5 (21.7)      1 (4.3)      0 (0)                  1 (5)        
                                                                                                                     
  Severity                                                                                                           0.246
   Mild                                               13 (56.5)     19 (82.6)    11 (68.8)              12 (60)      0.035
   Moderate                                           10 (43.5)     4 (17.4)     5 (31.3)               8 (40)       0.068
                                                                                                                     
  Boston.SSS                                          20.52±10.05   22.43±7.75   27.31±7.60             25.60±4.25   \<0.001
                                                                                                                     
  Boston.FSS                                          21.52±10.56   18.30±9.49   25.38±8.34             19.20±3.43   \<0.001
                                                                                                                     
  Grip strength                                       23.28±7.60    20.04±6.91   14.06±6.45             15.65±4.78   0.422
                                                                                                                     
  Pinch strength                                      6.76±1.48     5.80±2.09    3.75±1.92              5.85±1.51    \<0.001
                                                                                                                     
  VAS                                                 6.30±2.58     6.74±2.78    7.19±2.14              6.00±0.97    0.422

Values are presented as mean±standard deviation or number (%).

BMI, body mass index; Boston, Boston carpal tunnel questionnaire; SSS, symptom severity scale; FSS, functional status scale; VAS, visual analogue scale.

BMI (kg/m^2^): normal, 18.5--24.9; overweight, 25.0--29.9; obesity grade I, 30.0--34.9; obesity grade II, 35.0--39.9.

###### 

Postintervention mean for mild and moderate group and the whole sample

  Outcome                Mild[\*](#tfn5-jer-14-6-1067){ref-type="table-fn"}   Moderate[\*](#tfn5-jer-14-6-1067){ref-type="table-fn"}   Total                                      
  ---------------------- ---------------------------------------------------- -------------------------------------------------------- ----------------- ------- ---------------- -------
  Boston.SSS                                                                  0.26                                                                       0.449                    0.104
   Exercise+gabapentin   19.91±8.5                                                                                                     15.40±7.99                18.50±8.36       
   Exercise              15.31±9.48                                                                                                    18.90±10.46               16.87±9.85       
   Gabapentin            20.42±5.33                                                                                                    16.00±3.65                19.65±5.29       
   Control               20.92±3.15                                                                                                    21.88±5.25                21.30±4.01       
                                                                                                                                                                                  
  Boston.FSS                                                                  0.701                                                                      0.023                    0.895
   Exercise+gabapentin   24.45±6.23                                                                                                    17.20±7.16^a)^            22.19±7.19       
   Exercise              16.85±11.55                                                                                                   21.90±10.00^b)^           19.04±10.97      
   Gabapentin            17.84±8.98                                                                                                    16.75±7.18                17.65±8.56       
   Control               16.75±3.55                                                                                                    17.25±2.71                16.95±3.17       
                                                                                                                                                                                  
  Grip strength                                                               0.048                                                                      0.021                    0.023
   Exercise+gabapentin   19.86±8.35^a)^                                                                                                16.40±9.40^a)^            18.78±8.53^a)^   
   Exercise              25.69±4.03                                                                                                    22.75±7.80                24.41±6.00       
   Gabapentin            20.16±5.89                                                                                                    22.50±1.73                20.57±5.44       
   Control               16.08±3.87^b)^                                                                                                18.38±6.35^b)^            17.00±4.98       
                                                                                                                                                                                  
  Pinch strength                                                              0.619                                                                      0.001                    0.19
   Exercise+gabapentin   5.64±2.09                                                                                                     6.10±2.38^a)^             5.78±2.11        
   Exercise              7.42±1.22                                                                                                     7.10±1.93^b)^             7.28±1.54        
   Gabapentin            6.40±1.62                                                                                                     7.75±1.26^b)^             6.63±1.63        
   Control               6.17±1.15                                                                                                     7.13±2.23^b)^             6.55±1.69        
                                                                                                                                                                                  
  VAS                                                                         0.778                                                                      0.015                    0.187
   Exercise+gabapentin   4.30±2.06                                                                                                     4.20±2.28^a)^             4.27±2.05        
   Exercise              4.15±2.23                                                                                                     4.70±2.63^b)^             4.39±2.37        
   Gabapentin            5.11±2.18                                                                                                     2.00±2.83                 4.57±2.54        
   Control               4.75±1.06                                                                                                     5.00±1.07^b)^             4.85±1.04        

SD, standard deviation; Boston, Boston carpal tunnel questionnaire; SSS, symptom severity scale; FSS, functional status scale; VAS, visual analogue scale.

Analysis of covariance - adjusted for baseline measurements, age, gender, body mass index (BMI).

Analysis of covariance - adjusted for baseline measurements, age, gender, BMI, severity of the disease.

Different letters (^a,b^) indicate significant differences (group marked by letter ^a)^shows significantly better performance).
